What is the appropriate management for a patient who developed a fixed drug eruption prior to admission while receiving meropenem (carbapenem) and teicoplanin (glycopeptide) for sepsis?

Management of Fixed Drug Eruption in a Septic Patient on Meropenem and Teicoplanin

Immediately discontinue the most likely offending agent (meropenem or teicoplanin) and switch to an alternative antibiotic that maintains adequate sepsis coverage while avoiding cross-reactivity with the causative drug. For a patient with sepsis who developed a fixed drug eruption prior to admission while receiving meropenem and teicoplanin, antimicrobial therapy must not be interrupted, but the culprit drug must be identified and avoided.

Immediate Actions

Identify and discontinue the offending agent while maintaining appropriate antimicrobial coverage for sepsis. The Surviving Sepsis Campaign guidelines mandate that antimicrobial therapy be initiated within one hour for sepsis and septic shock, and this principle extends to maintaining uninterrupted coverage when switching agents 1.

Determining the Culprit Drug

• Meropenem is more commonly associated with cutaneous reactions (rash reported in 1.9% of patients) 2
• Teicoplanin (a glycopeptide) can cause various dermatological adverse reactions, though less frequently than vancomycin 3
• Fixed drug eruptions can occur with both carbapenems 4 and glycopeptides 3
• If the timing and distribution of lesions suggest one agent over the other, prioritize discontinuing that drug first

Antibiotic Substitution Strategy

If Meropenem is the Suspected Culprit:

Switch to aztreonam plus vancomycin (or continue teicoplanin if tolerated). Aztreonam has no cross-reactivity with carbapenems for IgE- or T-cell-mediated hypersensitivity and can be safely administered without prior testing in patients with carbapenem reactions 5. This combination provides:

• Gram-negative coverage (aztreonam)
• Gram-positive coverage (glycopeptide)
• Broad-spectrum empiric therapy as required by sepsis guidelines 1

Alternative option: Imipenem-cilastatin may be considered if the fixed drug eruption was specifically to meropenem, as successful substitution has been reported 4. However, this carries theoretical cross-reactivity risk and should only be used if aztreonam-based regimens are inadequate for the infection source.

If Teicoplanin is the Suspected Culprit:

Continue meropenem and add an alternative agent for gram-positive coverage such as:

• Linezolid (no cross-reactivity with glycopeptides)
• Daptomycin (for non-pneumonia infections)
• Do not substitute vancomycin - cross-reactivity between glycopeptides occurs, and vancomycin cannot be considered a safe alternative for patients with teicoplanin reactions 3

If Both Drugs are Suspected:

Switch to aztreonam plus linezolid to provide broad-spectrum coverage without either drug class.

Dermatologic Management

While maintaining antimicrobial therapy:

• Supportive care for the fixed drug eruption (topical corticosteroids, antihistamines)
• Monitor for progression to more severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) 2, 6
• Document the reaction clearly in the medical record to prevent future re-exposure

Antimicrobial Stewardship Principles

Daily reassessment is mandatory 1:

• De-escalate to targeted therapy once culture results and sensitivities are available (typically within 3-5 days) 1
• Typical duration is 7-10 days for most serious infections associated with sepsis 1
• Optimize dosing based on pharmacokinetic/pharmacodynamic principles, particularly in critically ill patients 1, 7

Critical Pitfalls to Avoid

1. Never discontinue all antimicrobials simultaneously - sepsis requires uninterrupted coverage 1
2. Do not assume glycopeptides are interchangeable - cross-reactivity exists between vancomycin and teicoplanin 3
3. Avoid carbapenems as a class if severe delayed cutaneous reaction - though cross-reactivity between carbapenems is low (0.87%) 5, fixed drug eruptions may recur with class members
4. Do not delay switching - continued exposure to the offending agent can worsen the eruption and potentially progress to life-threatening reactions 6

The priority is maintaining adequate antimicrobial coverage for sepsis while eliminating the causative agent of the drug eruption - this requires immediate substitution rather than observation, as mortality from untreated sepsis far exceeds the morbidity of most fixed drug eruptions.